Within this context, a placebo-controlled trial in patients with T1DM that were treated with liraglutide or placebo reported that the use of this drug resulted in a decrease in the levels of IL-6, IL-8, IL-10, and INF-γ after the 26 weeks of treatment, although this decrease was only significant for IL-6 [125]. This evidence concerns the gene IL6 and type 1 diabetes mellitus.